Drug Target Review2025-11-13T13:00:14
Pioneering circular RNA could redefine what the future of gene therapy looks like. Erik Digman Wiklund, CEO of Circio, shares how his company’s platform is enhancing gene expression and tackling toxicity challenges through smarter design and scientific collaboration.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-16T07:00:00Z
Author Dr Martin Baraibar
2026-11-13T07:00:00Z
Contributor Dr Panos Roussos, Drug Target Review
2025-06-02T10:00:00
Contributor Professor Stefan Trapp, Drug Target Review
2026-06-04T07:05:00
Author Graham Craig
2026-06-02T15:00:00
Sponsored by Danaher
2025-09-18T12:00:00
Sponsored by Benchling
2025-05-28T14:00:00
Sponsored by Eurofins DiscoverX
2024-01-24T12:52:38
Sponsored by BellBrook Labs
Site powered by Webvision Cloud